Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.
Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...
Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...
Pfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its oncology drug, Braftovi (encorafenib), for treating patients with ...
Zacks.com on MSN6d
PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFSPfizer PFE announced positive top-line results from the progression-free survival (PFS) analysis of a late-stage study of its ...
Analysts expect the New York-based company to report quarterly earnings at 46 cents per share, up from 10 cents per share in ...
Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...
Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback